The Board will hold a public hearing (on a date to be determined no later than February 27, 2019) to determine whether Horizon Therapeutics Canada is selling or has sold PROCYSBI (cysteamine bitartrate) in any market in Canada at a price that, in the Board's opinion, is or was excessive; and if so, what order, if any, should be made to remedy the excessive pricing.
News Release; Notice of Hearing; Statement of Allegations of Board Staff
Related Publications & Articles
-
Update on biosimilars in Canada – March 2023
In this article, we provide a further update on developments regarding biosimilars in Canada.Read More -
CADTH consultation on time-limited reimbursement initiative, and IMC report on what Canada can learn from Europe
The Canadian Agency for Drugs and Technologies in Health has released a consultation document for a Proposed Process for Time-limited Reimbursement Recommendations.Read More -
House of Commons Standing Committee on Health meets for study of the PMPRB
The Standing Committee on Health (HESA) of the House of Commons met on Thursday, April 27, 2023, to begin its study of the Patented Medicine Prices Review Board (PMPRB).Read More